

1 **Immune response induced by the Recombinant Novel Coronavirus Vaccine (Adenovirus**  
2 **Type 5 Vector) (Ad5-nCoV) in persons living with HIV (PLWH)**

3 **Immune response induced by the Recombinant Novel Coronavirus Vaccine in persons**  
4 **living with HIV**

5 **P. Cahn<sup>1</sup>, L. Barreto<sup>5</sup>, M.I. Figueroa<sup>1</sup>, V. Fink<sup>1</sup>, M.J. Rolon<sup>2</sup>, G. Lopardo<sup>3</sup>, I. Casetti<sup>4</sup>, M.**  
6 **Ceschel<sup>1</sup>, P. Patterson<sup>1</sup>, L. Gambardella<sup>1</sup>, G. Miernes<sup>1</sup>, A. Nava<sup>1</sup>, J. Gou<sup>5</sup>, R. Wang<sup>5</sup>, T.**  
7 **Zhu<sup>5</sup>, S.A. Halperin<sup>6</sup>**

8 **Authors**

9 P. Cahn, PhD (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
10 L. Barreto (5) 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District,  
11 Tianjin, PRC  
12 M.I. Figueroa, MD. (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
13 V. Fink, MD (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
14 M.J. Rolón, MD. (2) Av. Cerviño 3356, Buenos Aires, C1425AGP, Argentina  
15 G. Lopardo, MD. (3) 25 de Mayo 464, Buenos Aires, C1002 ABJ, Argentina  
16 I. Casetti, MD (4) Perú 1511, Buenos Aires, C1141ACG, Argentina  
17 M. Ceschel, bachelor's degree, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
18 P. Patterson, MD (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
19 L. Gambardella, DMD, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
20 G. Miernes, bachelor's degree, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
21 A. Nava, MD, (1) Av. Forest 345, Buenos Aires, C1427CEA, Argentina.  
22 J. Gou (5) 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District,  
23 Tianjin, PRC

24 R. Wang, PhD (5) 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin,

25 PRC

26 T. Zhu (5) 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District,

27 Tianjin, PRC

28 S.A. Halperin (6) 5980 University Ave #5850, Halifax, NS B3K 6R8, Canadá

29

30 **Institution:**

31 1 Fundación Huésped, Research Department, Ciudad Autónoma de Buenos Aires, Argentina,

32 2 Hospital Juan A. Fernández, Ciudad Autónoma de Buenos Aires, Argentina,

33 3 FUNCEI, Ciudad de Buenos Aires, Argentina,

34 4 Helios Salud, Ciudad de Buenos Aires, Argentina,

35 5 CanSino Biologics Inc, Tianjin, China,

36 6 Canadian Center for Vaccinology, Dalhousie University, Halifax, Canada

37

38 **Corresponding Author**

39 Pedro Cahn.

40 Research Department, Fundación Huésped, Av. Forest 345, Buenos Aires, 1427, Argentina.

41 Phone: 54 11 4981 7777

42 Email: [pedro.cahn@huesped.org.ar](mailto:pedro.cahn@huesped.org.ar)

43

44

45 **Summary:**

46 **Background:** Despite higher risk of poorer outcomes and potential sub-optimal vaccine  
47 effectiveness, people living with HIV (PLWH) are underrepresented in SARS-CoV-2 vaccine  
48 trials. We evaluated the safety and immunogenicity of the Ad5-nCoV vaccine (CanSino Biologics  
49 Inc./The Beijing Institute of Biotechnology) in PLWH.

50  
51 **Methods:** In this single arm, open-label Phase 2b trial, PLWH were enrolled in Argentina.  
52 Participants received two doses of Ad5-nCoV vaccine (intramuscular, dosage  $5 \times 10^{10}$  viral  
53 particles) at days 0 and 56. The primary outcomes were safety as serious adverse events [SAE],  
54 solicited and unsolicited local and systemic adverse events, impact on HIV viral load and CD4  
55 counts and immunogenicity measured by S-RBD IgG and pseudo-virus neutralizing antibodies  
56 (nAbs) up to 52 weeks (ClinicalTrials.gov:NCT05005156).

57  
58 **Findings:** Between June 2021-January 2022, 140 PLWH received at least one dose of Ad5-nCoV  
59 vaccine. At baseline, the majority were on antiretroviral therapy (99.3%), virologically suppressed  
60 (93.6%), with a median (IQR) CD4-cell count:736 (531-946) cells/ul. At baseline, 38 (27%)  
61 participants were seropositive for S-RBD antibodies, and 40 (28%) for nAbs. There were no SAEs  
62 related to the vaccine. Solicited AE within 7 days after first and second dose occurred in 93 (69%)  
63 and 75 (60%) participants, mostly grade 1, included pain, drowsiness and headache. The incidence  
64 of unsolicited AE within 28 days of vaccination was 10.7%. There were no significant changes in  
65 plasma viral load, CD4, CD4/CD8 ratio and no new AIDS-defining illnesses were reported. There  
66 were significant increases in the geometric mean titers (GMT) of S-RBD and nAbs between

67 baseline to week 52. Seroconversion rates 28 days after the first and second doses (day 84) were  
68 80% and 94% for S-RBD, and 35% and 78% for nAbs.

69

70 **Interpretation:** Two doses of the Ad5-nCoV vaccine were safe and induced an adequate immune  
71 response in virologically suppressed PLWH, maintaining high antibody titers at least during the  
72 first year post-vaccination.

73

74 **Funding:** CanSino Biologics Inc, Tianjin, China

75 **Key words: HIV - VACCINE - SARS-COV - IMMUNE RESPONSE**

76

77

78

79

## Introduction

80 In March 2020, the World Health Organization declared a global pandemic caused by SARS-CoV-  
81 2 (COVID-19). Four years later (March 2024), there have been more than 774 million reported  
82 cases and more than 7 million deaths [1]. People living with HIV (PLWH) are at increased risk of  
83 worse clinical outcomes after COVID-19 infection, particularly those with lower CD4-cell counts  
84 or not receiving antiretroviral therapy (ART)[2,3].

85 Vaccines have played a key role in the public health response to the COVID-19 pandemic. Indeed,  
86 shortly after the declaration of the global COVID-19 pandemic, a number of vaccines were rapidly  
87 developed and proved to be safe and efficacious in preventing symptomatic COVID-19[4]. In  
88 addition, despite lower vaccine effectiveness against variants of concern, their protection against  
89 severe COVID-19 has remained high[5].

90 Despite higher risk of poorer outcomes and potential sub-optimal vaccine effectiveness, PLWH  
91 have been largely underrepresented in pivotal COVID-19 vaccine trials. PLWHIV represented  
92 only 1% (1,557) out of a total number of approximately 150,000 participants enrolled in phase 2/3  
93 trials evaluating the mRNA-1273/Moderna, BNT162b2/Pfizer-BioNTech,  
94 ChAdOx1/AstraZeneca, NVX-2373/Novavax and Ad26.COV2.S/Janssen vaccines, with other  
95 studies completely excluding them[6].

96 To our knowledge, only three trials aimed to address concerns of a potential reduced immune  
97 response to COVID-19 vaccines among PLWH: two assessed the ChAdOx1/AstraZeneca

98 vaccine[7,8] and one the NVX-2373/Novavax vaccine[9]. In these studies, two doses of COVID-  
99 19 vaccines were found to be safe and immunogenic among PLWH, particularly among SARS-  
100 CoV-2 baseline-seropositive participants. Despite these promising results, sample sizes were small  
101 (ranging from 52 to 122), only evaluated two types of vaccines and were conducted in only two  
102 countries (UK and South Africa), highlighting the need for additional high-quality experimental  
103 studies in PLWH. This is particularly important for SARS-CoV-2 vaccines based on adenovirus  
104 type-5 (Ad5) platforms, given prior concerns associated with higher risk of HIV acquisition in  
105 participants of Ad5 vectored HIV-1 vaccine trials[10]. Although follow-up data from one of these  
106 studies did not find increased risk of HIV progression among participants who became HIV-  
107 infected[11], it remains critical to monitor the effects of other Ad-5-based vaccines on HIV  
108 infection and progression. Therefore, the objective of this study was to assess the safety and  
109 immunogenicity of two doses of Ad5-nCoV/ CanSino Biologics Inc./The Beijing Institute of  
110 Biotechnology in PLWH.

111

## 112 **Methods**

### 113 **Study design**

114 The original protocol (version 1.0) included a 52-week randomized placebo-controlled clinical  
115 trial evaluating the safety and immunogenicity of one dose of the Ad5-nCoV vaccine in PLWHIV  
116 on stable ART and virologically suppressed. The rapid advancement of the Argentinean COVID  
117 vaccination program reduced the possibilities of recruiting the study under such design.  
118 Accordingly, the study was amended on October 6<sup>th</sup>, 2021 to change the study design to a Phase  
119 IIb, multicentre, open-label, single-arm trial evaluating the safety and immunogenicity of two  
120 doses of the Ad5-nCoV vaccine in PLWHIV (version 1.5). Exclusion criteria based on plasma

121 HIV viral load or ART status were also removed. The trial was conducted in four sites in Buenos  
122 Aires, Argentina between May 31, 2021, and January 13, 2023, in accordance with the Declaration  
123 of Helsinki and Good Clinical Practice guidelines. All participants gave their written informed  
124 consent. The study was approved by ANMAT (Argentina's regulatory agency) and by the  
125 Institutional Review Boards at each participating site, and is registered in [clinicaltrials.gov](https://clinicaltrials.gov):  
126 NCT05005156.

127

## 128 **Participants**

129 We enrolled clinically stable adults (18 years and older) living with HIV who were free from  
130 opportunistic infections or AIDS-defining illness for at least six months before screening.  
131 Participants were excluded if they had a history of laboratory-confirmed SARS-CoV-2 infection,  
132 receipt of an adenovirus-vectored, coronavirus, or SARS-CoV-2 vaccine, any AIDS-defining  
133 illness, any medical or psychiatric unstable condition (including immunosuppression conditions  
134 other than HIV) that in the opinion of the investigator could preclude safe participation in the  
135 study, current substance use disorder or history of anaphylaxis to any vaccine component. Women  
136 who were pregnant or breastfeeding were not eligible to participate, and all participants involved  
137 in heterosexual sexual activity had to agree to the use of approved contraceptive methods.

138

## 139 **Procedures**

140 Eligible and consenting participants received two standard 0.5 mL/vial (i.e.,  $5 \times 10^{10}$ vp)  
141 intramuscular doses of the Ad5-nCoV vaccine in the deltoid region given eight weeks apart (i.e.,  
142 day 0 and 56), administered by trained study personnel. The Ad5-nCoV vaccine was produced as  
143 previously described[12].

144 All participants were contacted on a weekly basis (email, telephone, text message) to assess for  
145 any symptoms of COVID-19. The presence of any possible COVID-19 symptoms triggered  
146 laboratory testing for SARS-CoV-2 infection via PCR.

147 Participants were also asked to complete electronic or paper diaries reporting solicited adverse  
148 events (AEs) for 7 days and unsolicited AEs for 28 days after both the first and second vaccination.

149 Serious adverse events (SAE) and medically attended adverse events (MAAE) were collected  
150 throughout the 52-week duration of the trial and recorded every 4 weeks via telephone calls.

151 A baseline SARS-CoV-19 antibody, and a urine pregnancy test in women of child-bearing  
152 potential was performed on Day 0, immediately before vaccination. Blood samples for  
153 immunogenicity analysis were collected on days 0, 28, 84, and weeks 24 and 52. Immunogenicity  
154 measures included IgG antibodies to the receptor-binding domain of the SARS-CoV-2 spike  
155 protein 9 (S-RBD IgG antibody), measured by ELISA-based assays and neutralising antibodies  
156 against SARS-CoV-2 (nAbs), measured by pseudovirus neutralisation assays. HIV viral load, CD4  
157 and CD8-cell counts were measured on day 0, and weeks 24 and 52.

158

## 159 **Outcomes**

160 The two co-primary outcomes were the safety and immunogenicity profile of the Ad5-nCoV  
161 vaccine. Safety was assessed by the incidence of solicited and unsolicited AE occurring within 7  
162 and 28 days of each vaccination, respectively, SAE and MAAE throughout the study period, as  
163 well as HIV viral load at weeks 24 and 52. Immunogenicity was evaluated by the seroconversion  
164 rate of the S-RBD IgG antibody on Day 28, Day 84, Week 24, and Week 52 after vaccination.

165 Secondary safety outcomes included the incidence of a decrease in CD4-cell count by  $\geq 20\%$  as  
166 well as the change of the CD4/CD8 ratio from the baseline value. Secondary immunogenicity



167 outcomes included the seroconversion rate of nAbs, as well as the geometric mean titer (GMT)  
168 and geometric mean increase (GMI) of the S-RBD IgG antibody and nAbs at Day 28, Day 84, and  
169 Week 24 and Week 52 after vaccination.

170 Exploratory outcomes included the efficacy of two doses of Ad5-nCoV in preventing PCR-  
171 confirmed symptomatic COVID-19 occurring 14 and 28 days after the second dose (i.e., days 70  
172 and 84) up to last study visit.

173

#### 174 **Statistical analysis**

175 Given that this was a non-comparative study; no formal sample size calculation was performed.

176 The safety analysis population included all participants who received at least one dose of the Ad5-  
177 nCoV vaccine. Separate safety analyses were conducted for the first and second doses. Safety  
178 endpoints were summarized using frequency counts and percentages. The immunogenicity  
179 analysis population included participants with at least one dose of the vaccine and available  
180 antibody results. GMT, GMI, and seroconversion rate (with corresponding 95% confidence  
181 intervals) were calculated for each time point, using mixed effects linear regression models to  
182 assess changes over time. The seroconversion rate was calculated as the proportion of participants  
183 that had a GMI of the S-RBD IgG antibody or nAbs equal to or greater than 4 from baseline at  
184 each pre-specified time point. At baseline, participants with S-RBD IgG antibody or nAbs titers  
185 greater than 4 were considered positive. The evaluation of changes in the proportion of participants  
186 with undetectable VL, log<sub>10</sub> VL, CD4/CD8-cell counts and CD4/CD8 ratio was performed fitting  
187 a mixed effects linear regression model, setting as fixed independent variable the time as a  
188 continuous variable, and subject as random term.

189 The analysis of the exploratory efficacy endpoint was descriptive and performed in the total  
190 participants that were vaccinated with two doses.

191 All statistical analysis was performed using R Statistical Software[13].

192

## 193 **Results**

### 194 **Baseline characteristics**

195 Between May 31, 2021 and January 6, 2022, 141 PLWHIV were enrolled in this study. Of these,  
196 140 participants received at least one dose of the Ad5-nCoV vaccine (one participant withdrew  
197 consent before receiving any dose) and were included in this analysis: 133 participants received  
198 two doses and 7 participants one dose. Figure 1 shows the CONSORT flow diagram of participants  
199 and Table 1 summarizes the participants' baseline sociodemographic and clinical characteristics.  
200 The median age was 41 (Interquartile range [IQR]: 31-48), 79.0% were males and 97.9% self-  
201 reported white race. All except one participant (n=139, 99.3%) were on ART, the majority (93.6%)  
202 were virologically suppressed (VL <40 copies/mL) and the median (IQR) CD4-cell count was 736  
203 (531-946) cells/ul. At baseline, 38 (27%) participants were seropositive for S-RBD antibodies, and  
204 39 (28%) were seropositive for nAbs.

205

206 **Table 1. Baseline characteristics of the study population (N=140)**

207

<b>Age - median (IQR*)</b>	<b>41 (31-48)</b>
<b>Sex - % (95%CI) [n]</b>	

<b>Male</b>	<b>79% (70.7-84.9) [110]</b>
<b>Female</b>	<b>21% (15.1-29.3) [30]</b>
<b>Race - % (95%CI) [n]</b>	
<b>White</b>	<b>97.9% (93.4-99.4) [137]</b>
<b>American Indian or Alaska Native</b>	<b>0.7% (0.4-4.5) [1]</b>
<b>Black</b>	<b>0.7% (0.4-4.5) [1]</b>
<b>Other</b>	<b>0.7% (0.4-4.5) [1]</b>
<b>on Antiretroviral therapy - % (95%CI) [n]</b>	<b>99.3% (97.9-100) [139]</b>
<b>Virologically suppressed /≤ 40 copies per mL- % (95%CI) [n]</b>	<b>93.6% (87.8-96.8) [131]</b>
<b>CD4 count (cells/ul) - median (IQR*)</b>	<b>735.5 (530.5-945.8)</b>

208 \*median (percentiles 25-75).

209

## 210 Safety analysis

211 Solicited AE diaries were completed by 135 participants (96%) after the first dose, and 125  
 212 participants (94%) after the second dose. The proportion of participants reporting solicited  
 213 systemic and local AE after the first and second dose are presented in Figure 2. After the first dose,  
 214 93 participants (69%) reported at least one solicited AE, mostly grade 1. Pain (48%) was the most

215 common local solicited AE and drowsiness (39%) and headache (34%) the most common systemic  
216 solicited AE. After the second dose, 75 participants (60%) reported at least one solicited AE. A  
217 similar pattern of solicited AE was observed after the first and second dose though the proportion  
218 of participants reporting systemic solicited AE was lower (25% drowsiness, 23% headache).  
219 The global incidence of unsolicited AE within 28 days of vaccination was 10.7% (15 events: 11  
220 events after the first dose and 4 events after the second dose). The most frequent one was asthenia  
221 (7 events), only one was grade 3, and none required hospitalization.  
222 Over the 52-week duration of the study, there were 8 SAEs (none of them related to the study  
223 vaccine). Two participants died, one due to myocardial infarction complicated with severe bilateral  
224 COVID pneumonia and the other due to fatal respiratory failure secondary to lung cancer.  
225 A total of 141 MAAEs in 70 participants (50%) were reported, including 18 COVID-19 confirmed  
226 cases and 33 suspected cases. Most of the MAAEs were grade 2 (74%). Two MAAEs were  
227 possibly related to the study drug: acute unilateral hearing loss and fever of unknown origin.  
228 HIV VL and CD4/CD8 cell count measurements at baseline, week 24 and 52 after the first vaccine  
229 dose are presented in Table 2. There were no significant changes in the proportion of participants  
230 who were virologically suppressed or the log<sub>10</sub> VL in non-suppressed participants between  
231 baseline and the other time points. The mixed effects linear regression model fit showed a  
232 statistically significant increase of CD4, CD8-cell count mean, as well as CD4/CD8 ratio mean  
233 over time ( $p < 0.001$ )[14].  
234 A decrease of CD4-cell count of 20% or higher from baseline was observed in 22.6% of  
235 participants at week 24, and 12.2% at week 52. None of these participants had less than 200 CD4  
236 cells per mL at any point in time, and there were no AIDS-defining illnesses during the  
237 observation period.

238 **Table 2. HIV viral load, CD4 and CD8 cell count measurements at baseline, week 24 and**  
 239 **week 52 after the first Ad5-CoV vaccine dose**  
 240

	<b>Baseline (n=140)</b>	<b>Week 24 (n=124)</b>	<b>Week 52 (n=123)</b>	<b>p-value</b>
<b>Virologically suppressed (<math>\leq</math> 40 copies/ mL), n (%)</b>	131 (94)	113 (91)	112 (91)	0.199
<b>log<sub>10</sub> HIV-VL in non-suppressed participants, median (IQR)</b>	3.38 (2.37-4.59)	2.38 (1.74-3.78)	1.97 (1.77-3.46)	0.062
<b>CD4-cell count, median (IQR)</b>	735 (530.5-945.8)	703.5 (515.8-940.5)	789 (620-996.5)	<b>&lt;0.001</b>
<b>CD8-cell count, median (IQR)</b>	886 (699-1144)	833 (635.25-1059.5)	1045 (751-1328)	<b>&lt;0.001</b>
<b>CD4/CD8 ratio</b>	0.80 (0.57-1.16)	0.85 (0.60-1.14)	0.82 (0.55-1.10)	<b>&lt;0.001</b>

241

## 242 Immunogenicity analysis

243 Immunogenicity analysis included samples from the 140 participants who received at least one  
244 vaccine dose and had available S-RBD antibodies and n-Abs results, excluding samples taken after  
245 COVID-19 confirmed cases: 139 samples for day 0, 135 for day 28, 127 for day 84, 104 for week  
246 24, and 73 for week 52. Sixty-four samples were excluded due to SARS-CoV-2 confirmed  
247 infection. Tables 3 and 4 present GMT, GMI, and seroconversion rates at pre-specified time points  
248 for S-RBD antibodies and nAbs, respectively.

249 At baseline, the GMT of S-RBD antibodies was 7.02 (95% Confidence Interval 5.79-8.51), with  
250 38 (27%) participants being categorized as seropositive for S-RBD antibodies. The Ad5-CoV  
251 vaccine elicited a strong anti-S-RBD antibody response, which increased after the second dose.  
252 There were statistically significant increases in the S-RBD GMT between baseline and all the other  
253 visits. Seroconversion of the anti-RBD antibodies occurred in 108/135 (80%) participants on day  
254 28, 118/127 (93%) on day 84, 87/104 (84%) on week 24, and 61/73 (84%) on week 52. Five  
255 subjects never reached S-RBD seroconversion.

256 At baseline, the GMT of nAbs was 5.54 [95% CI 4.88 – 6.30], with 40 (28.1%) participants being  
257 categorized as sero-positive for nAbs. nAbs seroconversion occurred in 47/135 (35%) participants  
258 at day 28, 99/127 (78%) at day 84; 59/104 (57%) at week 24 and 57/73 (78%) at week 52. There  
259 were 21 subjects who did not reach seroconversion of nAbs titers at any time point.

260 Post-hoc analyses indicated that although there was a significant increase in the GMT of S-RBD  
261 antibodies and nAbs in both SARS-Cov-2 sero-positive and sero-negative participants, GMT were  
262 significantly higher in sero-positive participants at all time points. Of note, it appears that the GMI  
263 rate after the second dose was higher in the SARS-Cov-2 sero-negative group(supplementary  
264 figure).

265

266 **Table 3. S-RBD antibodies at pre-specified time points after vaccination\*  $p < 0.05$**

267

	<b>Day 0</b> <b>n=139</b>	<b>Day 28</b> <b>n=135</b>	<b>Day 84</b> <b>n=127</b>	<b>Day 168</b> <b>n=104</b>	<b>Day 364</b> <b>n=73</b>	<b>p-value</b>
GMCs of S-RBD antibodies. GMC (CI %)	7.02 (5.79 - 8.51)	103.04 (75.90 - 139.88)	260.21 (209.08 - 323.84)	17.46 (123.53 - 254.93)	395.29 (257.56 - 606.66)	<0.01*
**GMI of S-RBD antibodies. GMI (CI 95%)		14.56 (1.36-18.65)	35.57 (8.16-44.94)	22.92 (5.68-33.50)	46.20 (8.34-74.33)	
seroconversion, n (%)		108 (80)	118 (93)	87 (84)	61 (84)	

268 \*\* GMCs and CI 95% are presented. Comparison between visits were performed by Friedman test  
 269 for paired data on a logarithmic scale. Post-hoc analysis (pairwise comparisons) was performed by  
 270 Wilcoxon signed rank test with continuity correction, and Bonferroni's method for multiple  
 271 comparison correction was applied.

272 \*\*\*GMI (the geometric mean increase) was calculated as the geometric mean of the ratios of the  
 273 titer of the visit to the baseline titer.

274

275

276

277 **Table 4. SARS-CoV-2 neutralizing antibodies at pre-specified time points after vaccination**

	<b>Day 0</b> n=139	<b>Day 28</b> n=135	<b>Day 84</b> n=127	<b>Day 168</b> n=104	<b>Day 364</b> n=73	<b>p-value</b>
** GMTs of SARS-CoV- 2 neutralizing antibodies. GMT (CI 95%)	5.54 (4.88- 6.30)	15.73 (11.71- 21.14)	46.10 (35.88- 59.24)	36.17 (25.35- 51.62)	73.94 (50.16- 108.99)	<0.01*
** GMI of SARS-CoV- 2		2.83 (2.26- 3.54)	8.15 (6.64- 9.98)	6.12 (4.43- 8.45)	11.64 (7.94- 17.08)	



neutralizing antibodies. GMI (CI 95%)						
Seroconversion, n (%)		47 (35)	99 (78)	59 (57)	57 (78)	

278

279

## 280 Exploratory efficacy analysis

281 There were 45 PCR-confirmed COVID cases among the 133 participants who received two  
 282 vaccine doses. Of these, 42 (31.6%) occurred within 14 days after the second dose: 1 case between  
 283 14 and 28 days after the second dose, and 41, between 28 days and 52 weeks. None of the COVID  
 284 confirmed cases met severe disease criteria. The median time between the application of the second  
 285 dose and the start date of COVID-19 was 135 days (IQR:81-193). Over half of the COVID-  
 286 confirmed cases (25/42) occurred in January 2022, when Argentina was in the midst of a new wave  
 287 of Covid-19 associated with the emergence of the Omicron variant.

288

289

## Discussion

290 Meta-analyses evaluating the immunogenicity and safety of COVID-19 vaccines in PLWH have  
 291 shown a favorable, though not optimal immune response to COVID-19 vaccines in PLWH[15].

292 While most studies have shown comparable seroconversion rates to the general population, results  
293 on the magnitude of the antibody response have been less consistent with some studies reporting  
294 no differences, and other showing lower antibody titers in PLWH. These disparities may be due to  
295 the high heterogeneity among studies, including study population, vaccine type, time between  
296 vaccine dose and serology testing and definition of seroconversion. Our study adds to the literature  
297 by evaluating for the first time an Ad5-nCoV vaccine in PLWH. We found that two doses of the  
298 Ad5-nCoV vaccine were well-tolerated and produced an adequate and sustained immune response  
299 in PLWH well controlled on ART in Argentina. In addition, the Ad5-nCoV vaccine had a neutral  
300 effect on HIV surrogate markers.

301 In this study, vaccination with Ad5-nCoV had a favourable safety profile with no vaccine-related  
302 SAEs, and most solicited AEs being mild in severity. These findings are similar to the previously  
303 reported safety profile in the general adult population enrolled in the phase 3 Ad5-nCoV trial[12].  
304 No significant changes in HIV surrogate markers as HIV plasma viral load were found, and CD4,  
305 CD8, and CD4/CD8 ratios remained stable across the observation period.

306 Consistent with prior meta-analysis[15,16], our results indicate a favorable immune response to  
307 the Ad5-nCoV vaccine in PLWH. For S-RBD antibodies, there was a GMI of almost 15 fold after  
308 the first dose, increasing to 35 fold after the second dose, with sustained GMT S-RBD antibodies  
309 for up to a year and seroconversion rates of more than 80% of participants. Development of a  
310 neutralising antibody response was lower, with a GMI of 2.8 and 8 fold after the first and second  
311 dose. The seroconversion rate after the first dose was only 35%, but increased to more than 75%  
312 after the second dose. The immune response to the Ad5-nCoV vaccine in PLWH in this study  
313 however, appeared to be lower than that observed after one dose of the Ad5-nCoV in the general  
314 adult population, particularly for nAbs. Altogether, these findings suggest that two doses of Ad5-

315 nCoV may be needed in PLWH to achieve adequate protection, given evidence indicating a strong  
316 correlation between nAbs and vaccine efficacy against COVID-19[17].

317 This study has some limitations. First, this was an open-label single arm study, without concurrent  
318 recruitment of adults without HIV, and thus post-hoc comparisons with the general population  
319 from the phase 3 Ad5-nCoV trial should be interpreted with caution. Second, we included PLWH  
320 who were mostly on ART, with well controlled HIV infection and good immunological status.  
321 Additionally, our study population predominantly consisted of white men. This may limit the  
322 generalizability of our findings to the overall population of PLWH, without previously considering  
323 their immunosuppression and ART status, sex or race. Third, although seroconversion rate is a  
324 proxy for vaccine efficacy, our study was not powered to evaluate clinical efficacy endpoints and  
325 the estimated sample size changed after the rapid advancement of the Argentinean COVID  
326 vaccination program. Also a limitation is the number of samples available for immunogenic  
327 analyzes through the 52 weeks.

328 In conclusion, two doses of the Ad5-nCoV vaccine were safe and induced an adequate immune  
329 response in virologically suppressed PLWH, maintaining high antibody titers at least during the  
330 first year post-vaccination. Future studies should evaluate the clinical efficacy of various  
331 immunization strategies with the Ad5-nCoV vaccine in a diverse population of PLWH (including  
332 those with more advanced immunosuppression) in preventing breakthrough infections and severe  
333 COVID-19 disease by emerging variants of concern.

334

### 335 **Contributors**

336 PC, LB, TZ, SH designed the study, and wrote the study protocol. MC,- GM, AN oversaw  
337 statistical analyses. PC, MIF, GL, IC, MJR, and MY accessed and verified the underlying data in

338 the manuscript. LG and the quality team led the implementation and study quality assurance. All  
339 authors had full access to all the data in the study and had final responsibility for the decision to  
340 submit for publication. All authors approved the final manuscript.

341

#### 342 **Declaration of interests**

343 PC received grant support to his institution from CanSino Biologics Inc. To carry out this study as  
344 an investigator initiative, Fundacion Huesped was responsible for site selection, study  
345 implementation, quality control and assurance, and general overview of the study. Other authors  
346 declare no competing interests.

347

#### 348 **Data sharing**

349 Fundacion Huesped and the Canadian Center for Vaccinology shared anonymised individual  
350 patient data with Cansino Biologic Inc.

351

#### 352 **Role of the funding source**

353 CanSino Biologics provided the vaccine and placebo, as well as the funds for the study.

354

#### 355 **Acknowledgements**

356 We want to acknowledge the invaluable and generous contributions of all study participants and  
357 their families, and of all the staff across the participant sites who supported recruitment and  
358 retention into the study. We acknowledge M. Eugenia Socias for her contribution to the writing of  
359 this manuscript, Javier Mariani and team for the statistical analysis, and Meixu Yan for the  
360 contribution, support and work on the manuscript.

361

362

363

364

365

366

367

368

369

## 370 **References**

371 1. COVID-19 Cases | WHO COVID-19 Dashboard Available online:

372 <https://data.who.int/dashboards/covid19/cases> (accessed on 5 July 2024).

373 2. Ambrosioni, J.; Blanco, J.L.; Reyes-Urueña, J.M.; Davies, M.-A.; Sued, O.; Marcos, M.A.;

374 Martínez, E.; Bertagnolio, S.; Alcamí, J.; Miro, J.M.; et al. Overview of SARS-CoV-2

375 Infection in Adults Living with HIV. *Lancet HIV* **2021**, *8*, e294–e305, doi:10.1016/S2352-

376 3018(21)00070-9.

377 3. Danwang, C.; Noubiap, J.J.; Robert, A.; Yombi, J.C. Outcomes of Patients with HIV and

378 COVID-19 Co-Infection: A Systematic Review and Meta-Analysis. *AIDS Res. Ther.* **2022**,

379 *19*, 3, doi:10.1186/s12981-021-00427-y.

380 4. Graña, C.; Ghosn, L.; Evrenoglou, T.; Jarde, A.; Minozzi, S.; Bergman, H.; Buckley, B.S.;

381 Probyn, K.; Villanueva, G.; Henschke, N.; et al. Efficacy and Safety of COVID-19

382 Vaccines. *Cochrane Database Syst. Rev.* **2022**, *12*, CD015477,

383 doi:10.1002/14651858.CD015477.

- 384 5. Zeng, B.; Gao, L.; Zhou, Q.; Yu, K.; Sun, F. Effectiveness of COVID-19 Vaccines against  
385 SARS-CoV-2 Variants of Concern: A Systematic Review and Meta-Analysis. *BMC Med.*  
386 **2022**, *20*, 200, doi:10.1186/s12916-022-02397-y.
- 387 6. Höft, M.A.; Burgers, W.A.; Riou, C. The Immune Response to SARS-CoV-2 in People  
388 with HIV. *Cell. Mol. Immunol.* **2024**, *21*, 184–196, doi:10.1038/s41423-023-01087-w.
- 389 7. Frater, J.; Ewer, K.J.; Ogbe, A.; Pace, M.; Adele, S.; Adland, E.; Alagaratnam, J.; Aley,  
390 P.K.; Ali, M.; Ansari, M.A.; et al. Safety and Immunogenicity of the ChAdOx1 NCoV-19  
391 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: A Single-Arm Substudy of a  
392 Phase 2/3 Clinical Trial. *Lancet HIV* **2021**, *8*, e474–e485, doi:10.1016/S2352-  
393 3018(21)00103-X.
- 394 8. Madhi, S.A.; Koen, A.L.; Izu, A.; Fairlie, L.; Cutland, C.L.; Baillie, V.; Padayachee, S.D.;  
395 Dheda, K.; Barnabas, S.L.; Bhorat, Q.E.; et al. Safety and Immunogenicity of the ChAdOx1  
396 NCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without  
397 HIV in South Africa: An Interim Analysis of a Randomised, Double-Blind, Placebo-  
398 Controlled, Phase 1B/2A Trial. *Lancet HIV* **2021**, *8*, e568–e580, doi:10.1016/S2352-  
399 3018(21)00157-0.
- 400 9. Madhi, S.A.; Moodley, D.; Hanley, S.; Archary, M.; Hoosain, Z.; Lalloo, U.; Louw, C.;  
401 Fairlie, L.; Fouche, L.F.; Masilela, M.S.L.; et al. Immunogenicity and Safety of a SARS-  
402 CoV-2 Recombinant Spike Protein Nanoparticle Vaccine in People Living with and without  
403 HIV-1 Infection: A Randomised, Controlled, Phase 2A/2B Trial. *Lancet HIV* **2022**, *9*,  
404 e309–e322, doi:10.1016/S2352-3018(22)00041-8.
- 405 10. Buchbinder, S.P.; McElrath, M.J.; Dieffenbach, C.; Corey, L. Use of Adenovirus Type-5  
406 Vectored Vaccines: A Cautionary Tale. *The Lancet* **2020**, *396*, e68–e69,

407 doi:10.1016/S0140-6736(20)32156-5.

408 11. Fitzgerald, D.W.; Janes, H.; Robertson, M.; Coombs, R.; Frank, I.; Gilbert, P.; Loufty, M.;

409 Mehrotra, D.; Duerr, A.; Step Study Protocol Team An Ad5-Vectored HIV-1 Vaccine

410 Elicits Cell-Mediated Immunity but Does Not Affect Disease Progression in HIV-1-

411 Infected Male Subjects: Results from a Randomized Placebo-Controlled Trial (the Step

412 Study). *J. Infect. Dis.* **2011**, *203*, 765–772, doi:10.1093/infdis/jiq114.

413 12. Halperin, S.A.; Ye, L.; MacKinnon-Cameron, D.; Smith, B.; Cahn, P.E.; Ruiz-Palacios,

414 G.M.; Ikram, A.; Lanas, F.; Guerrero, M.L.; Navarro, S.R.M.; et al. Final Efficacy

415 Analysis, Interim Safety Analysis, and Immunogenicity of a Single Dose of Recombinant

416 Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Adults 18 Years and Older: An

417 International, Multicentre, Randomised, Double-Blinded, Placebo-Controlled Phase 3 Trial.

418 *The Lancet* **2022**, *399*, 237–248, doi:10.1016/S0140-6736(21)02753-7.

419 13. R Foundation for Statistical Computing R: A Language and Environment for Statistical

420 Computing. Available online: <https://www.r-project.org/> (accessed on 22 April 2024).

421 14. Vergori, A.; Cozzi-Lepri, A.; Tavelli, A.; Mazzotta, V.; Azzini, A.M.; Gagliardini, R.;

422 Mastroianni, I.; Latini, A.; Pellicanò, G.; Taramasso, L.; et al. SARS-CoV-2 mRNA

423 Vaccination and Short-Term Changes in Viral Load and CD4/CD8 T Cell Counts in People

424 Living with HIV. *Int. J. Infect. Dis.* **2024**, *0*, doi:10.1016/j.ijid.2024.107065.

425 15. Søndergaard, M.H.; Thavarajah, J.J.; Churchill Henson, H.; Wejse, C.M. SARS-CoV-2

426 Vaccine Immunogenicity for People Living with HIV: A Systematic Review and Meta-

427 Analysis. *HIV Med.* **2024**, *25*, 16–37, doi:10.1111/hiv.13537.

428 16. Kang, L.; Shang, W.; Gao, P.; Wang, Y.; Liu, J.; Liu, M. Immunogenicity and Safety of

429 COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-

430           Analysis. *Vaccines* **2022**, *10*, 1569, doi:10.3390/vaccines10091569.

431    17. Khoury, D.S.; Schlub, T.E.; Cromer, D.; Steain, M.; Fong, Y.; Gilbert, P.B.; Subbarao, K.;

432           Triccas, J.A.; Kent, S.J.; Davenport, M.P. Correlates of Protection, Thresholds of

433           Protection, and Immunobridging among Persons with SARS-CoV-2 Infection. *Emerg.*


434           *Infect. Dis.* **2023**, *29*, 381–388, doi:10.3201/eid2902.221422.

435

436



**Figure 1. Consort Study Flow Chart**



medRxiv preprint doi: <https://doi.org/10.1101/2024.10.17.24315660>; this version posted October 17, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**Figure 2. Proportion of participants reporting solicited systemic (A) and local (B) adverse events in participants vaccinated with at least one dose of the Ad5-CoV vaccine, after first (left) and second (right) dose.**

The figure summarizes AEs at any day & grade up to 7 days after vaccination. Solicited AE diaries were completed by 135 participants after the first dose and 125 participants after the second dose.

